# Equillium, Inc. (EQ) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/EQ
## Company Profile
- Ticker: EQ
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunology
## Stock Data
- Close: 1.32 USD
- Market cap: 176402091.24 USD
- Last updated: 2026-10-13
## Business Overview
### Immunobiology Company
Equillium develops therapies for severe autoimmune and inflammatory disorders using mechanisms intended to restore immune balance.
### EQ504
EQ504 is a selective aryl hydrocarbon receptor modulator with a multimodal, non-immunosuppressive mechanism designed to support barrier function and regulate tissue inflammation.
### Local Delivery Strategy
Potential formulations include targeted gastrointestinal delivery for ulcerative colitis and inhaled delivery for inflammatory lung diseases.
## Why The Stock Is Moving

As of Oct 13, 2026, EQ closed down 12.0% at $1.32. No new same-company headline was identified in the current news window.

## Future Catalysts

- Initiation of the Phase 1 proof-of-mechanism study of EQ504 in the fourth quarter of 2026.
- Topline Phase 1 data for EQ504 approximately six months after study initiation.

## Recent News
- 2026-10-06 20:05 EST — [Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference](https://biopharmsignal.com/news/EQ/equillium-announces-poster-presentation-at-the-50th-anniversary-la-jolla-immunol-4c232416) — Source: Equillium, Inc.
- 2026-10-05 20:05 EST — [Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504](https://biopharmsignal.com/news/EQ/equillium-receives-australian-regulatory-clearance-to-initiate-first-in-human-cl-68afdbf7) — Source: Equillium, Inc.
- 2026-09-29 20:05 EST — [Equillium Announces Poster Presentations at the 7th International AHR Conference](https://biopharmsignal.com/news/EQ/equillium-announces-poster-presentations-at-the-7th-international-ahr-conference-52973051) — Source: Equillium, Inc.
- 2026-09-16 12:30 EST — [Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum](https://biopharmsignal.com/news/EQ/equillium-to-participate-in-stifel-s-2026-virtual-immunology-and-inflammation-fo-a844ce53) — Source: Equillium, Inc.
- 2026-09-02 12:30 EST — [Equillium to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/EQ/equillium-to-participate-in-upcoming-investor-conferences-f0a61d20) — Source: Equillium, Inc.